EICHORCondition: Hematologic Malignancies · Sponsor: Ascentage Pharma Group Inc.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.
This description comes directly from the study's public registry record.
Laura Glass · 301-520-5964 · Laura.Glass@ascentage.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Jacksonville, Florida, United States | Recruiting |
| Duke Unviersity | Durham, North Carolina, United States | Completed |
| MDACC | Houston, Texas, United States | Recruiting |
| St. Vincent Hospital | Fitzroy, Victoria, Australia | Recruiting |
| Epworth Healthcare | Richmond, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03537482